Top

Published in:

01-06-2011 | Preclinical study

PALB2 analysis in BRCA2-like families

Authors: M. A. Adank, S. E. van Mil, J. J. P. Gille, Q. Waisfisz, H. Meijers-Heijboer

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Abstract

BRCA2 and PALB2 function together in the Fanconi anemia (FA)–Breast Cancer (BRCA) pathway. Mono-allelic and bi-allelic BRCA2 and PALB2 mutation carriers share many clinical characteristics. Mono-allelic germline mutations of BRCA2 and PALB2 are risk alleles of female breast cancer and have also been reported in familial pancreatic cancer, and bi-allelic mutations cause a severe form of Fanconi anemia. In view of these similarities, we investigated whether the prevalence of PALB2 mutations was increased in breast cancer families with the occurrence of BRCA2 associated tumours other than female breast cancer. PALB2 mutation analysis was performed in 110 non-BRCA1/2 cancer patients: (a) 53 ovarian cancer patients from female breast-and/or ovarian cancer families; (b) 45 breast cancer patients with a first or second degree relative with pancreatic cancer; and (c) 12 male breast cancer patients from female breast cancer families. One truncating PALB2 mutation, c.509_510delGA, resulting in p.Arg170X, was found in a male breast cancer patient. We conclude that germline mutations of PALB2 do not significantly contribute to cancer risk in non-BRCA1/2 cancer families with at least one patient with ovarian cancer, male breast cancer, and/or pancreatic cancer.

Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22. doi:10.1038/ng.2007.53 PubMedCrossRef

Thompson D, Easton D, Breast Cancer Linkage Consortium (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410–419. doi:10.1086/318181 PubMedCrossRef

van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HFA, Ausems MGEM, Menko FH, Gomez Garcia EB, Klijn JMG, Hogervorst FBL, van Houwelingen JC, van ‘t Veer LJ, Rookus MA, van Leeuwen FE, Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42:711–719. doi:10.1136/jmg.2004.028829 PubMedCrossRef

Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8:735–748. doi:10.1038/nrg2159 PubMedCrossRef

Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingstone DM (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719–729. doi:10.1016/j.molcel.2006.05.022 PubMedCrossRef

Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161. doi:10.1038/ng1942 PubMedCrossRef

Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Gen 39:162–164. doi:10.1038/ng1947 CrossRef

Zhang F, Fan Q, Ren K, Andreassen PR (2009) PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 7:1110–1118. doi:10.1158/1541-7786 PubMedCrossRef

Alter BP, Rosenberg PS, Brody LC (2007) Clinical features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 44:1–9. doi:10.1136/jmg.2006.043257 PubMedCrossRef

10.

Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Williams Parsons D, Cheng-Ho Lin J, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue C, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217. doi:10.1126/science.1171202 PubMedCrossRef

11.

Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41:474–480. doi:10.1136/jmg.2003.017996 PubMedCrossRef

12.

Ameziane N, van den Ouweland AM, Adank MA, Vijzelaar RN, Errami A, Dorsman JC, Joenje H, Meijers-Heijboer H, Waisfisz Q (2009) Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer. Breast Cancer Res Treat 118:651–653. doi:10.1007/s10549-009-0428-8 PubMedCrossRef

13.

Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, The Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Gen 39:165–167. doi:10.1038/ng1959 CrossRef

14.

Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingstone DM (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci 104:16:6788–6793. doi:10.1073/pnas.0701724104

15.

Garcia MJ, Fernandez V, Osorio A, Barroso A, Llort G, Lazaro C, Blanco I, Caldes T, de la Hoya M, Ramon y Cajal T, Alonso C, Tejada M-I, San Roman C, Robles-Diaz L, Urioste M, Benitez J (2009) Analysis of FANCB and FANCN/PALB2 Fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 113:545–551. doi:10.1007/s10549-008-9945-0 PubMedCrossRef

16.

Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, CHEK2-Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59. doi:10.1038/ng879 PubMedCrossRef

17.

Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JGM, van Leeuwen FE, Russell NS, van ‘t Veer LJ (2004) Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 83:91–93. doi:10.1023/B:BREA.0000010697.49896.03 PubMedCrossRef

18.

Cao A-Y, Huang J, Hu Z, Li W-F, Ma Z-L, Tang L-L, Zhang B, Su F-X, Zhou J, Di G-H, Shen K-W, Wu J, Lu J-S, Luo J-M, Yuan W-T, Shen Z-Z, Huang W, Shao Z-M (2008) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114:457–462. doi:10.1007/s10549-008-0036-z PubMedCrossRef

19.

Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen S-M, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma V-M, Kataja V, Soini Y, Drapkin RI, Livingstone DM, Winqvist R (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319. doi:10.1038/nature05609 PubMedCrossRef

20.

Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E, Robidoux A, Martin G, Bismar TA, Tischkowitz M, Rousseau F, Narod SA (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9:R83. doi:10.1186/bcr1828 PubMedCrossRef

21.

McInerney NM, Miller N, Rowan A, Colleran C, Barclay E, Curran C, Kerin MJ, Tomlinson IP, Sawyer E (2009) Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat 121:203–210. doi:10.1007/s10549-009-0540-9 PubMedCrossRef

22.

Sluiter M, Mew S, van Rensburg EJ (2009) PALB2 sequence variants in young South African breast cancer patients. Fam Cancer 8:347–353. doi:10.1007/s10689-009-9241-0 PubMedCrossRef

23.

Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, Palli D (2009) A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer. doi:10.1007/s10689-009-9295-z

24.

Heikinnen T, Kärkkäinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, Blomqvist C, Nevanlinna H (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 15:3214–3222. doi:10.1158/1078-0432 CrossRef

25.

Gunnarsson H, Arason A, Gillanders EM, Agnarsson BA, Johannesdottir G, Johannsson OTh, Barkardottir RB (2008) Evidence against PALB2 involvement in Icelandic breast cancer susceptibility. J Negat Results Biomed 7:5. doi:10.1186/1477-5751-7-5 PubMedCrossRef

26.

Pakkanen S, Wahlfors T, Siltanen S, Patrikainen M, Matikainen MP, Tammela TLJ, Schleutker J (2009) PALB2 variants in hereditary and unselected Finnish prostate cancer cases. J Negat Results Biomed 8:12. doi:10.1186/1477-5751-8-12 PubMedCrossRef

27.

Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska P, Derlatka P, Cendrowski K, Kupryjanczyk J (2010) A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Gen 11:20. doi:10.1186/1471-2350-11-20 CrossRef

28.

Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A, Holter S, Rothenmund H, Ghadirian P, Foulkes WD, Gallinger S (2009) Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137:1183–1186. doi:10.1053/j.gastro.2009.06.055 PubMedCrossRef

29.

Sauty de Chalon A, Teo Z, Park DJ, Odefrey FA, kConFab, Hopper JL, Southey MC (2010) Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 121:253–255. doi:10.1007/s10549-009-0673-x PubMedCrossRef

30.

Silvestri V, Rizzolo P, Zanna I, Falchetti M, Masala G, Bianchi S, Papi L, Giannini G, Palli D, Ottini L (2010) PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat. doi:10.1007/s10549-010-0797-z

31.

Tischkowitz M, Sabbaghian N, Ray AM, Lange EM, Foulkes WD, Cooney KA (2008) Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate 68:675–678. doi:10.1002/pros.20729 PubMedCrossRef

Title: PALB2 analysis in BRCA2-like families
Authors: M. A. Adank
S. E. van Mil
J. J. P. Gille
Q. Waisfisz
H. Meijers-Heijboer
Publication date: 01-06-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1001-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI)

Soy consumption and breast cancer risk: four recent meta-analyses

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer

Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk

VEGF 936C>T polymorphism and breast cancer risk: evidence needed further clarification

Keynote webinar | Spotlight on antibody–drug conjugates in cancer